These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2322153)

  • 1. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis.
    Abelson MB; Paradis A; George MA; Smith LM; Maguire L; Burns R
    Arch Ophthalmol; 1990 Apr; 108(4):520-4. PubMed ID: 2322153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV; Udell IJ
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis-a controlled, double-blind clinical trial.
    Miller J; Wolf EH
    Ann Allergy; 1975 Aug; 35(2):81-6. PubMed ID: 1096685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Naphcon-A and its components (naphazoline and pheniramine) in a provocative model of allergic conjunctivitis.
    Dockhorn RJ; Duckett TG
    Curr Eye Res; 1994 May; 13(5):319-24. PubMed ID: 8055694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
    Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
    Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjunctival temperature: a measure of ocular decongestant and anti-inflammatory activity.
    Salem H; Dunn BJ; Loux JJ
    Ann Ophthalmol; 1975 Jun; 7(6):819-24. PubMed ID: 1147509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of topically applied occular decongestant and antihistamine.
    Abelson MB; Allansmith MR; Friedlaender MH
    Am J Ophthalmol; 1980 Aug; 90(2):254-7. PubMed ID: 7425039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
    Abelson MB; George MA; Schaefer K; Smith LM
    J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-masked comparison of ocular decongestants as therapy for allergic conjunctivitis.
    Lanier BQ; Tremblay N; Smith JP; deFaller JM
    Ann Allergy; 1983 Mar; 50(3):174-7. PubMed ID: 6338768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.
    Abelson MB; Kaplan AP
    Clin Ther; 2002 Mar; 24(3):445-56. PubMed ID: 11952027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.
    Figus M; Fogagnolo P; Lazzeri S; Capizzi F; Romagnoli M; Canovetti A; Iester M; Ferreras A; Rossetti L; Nardi M
    Eur J Ophthalmol; 2010; 20(5):811-8. PubMed ID: 20383847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New trends in the treatment of allergic conjunctivitis.
    Parys W; Blockhuys S; Janssens M
    Doc Ophthalmol; 1992; 82(4):353-60. PubMed ID: 1363981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
    Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
    Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.